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Lymphomas account for less than 5% of thyroid malignant lesions. Vast majority of them are B-cell non-Hodgkin
lymphomas (NHL), while Hodgkin lymphoma (HL) is extremely rare. Here we present two cases of HL, at baseline
manifesting as a thyroid lesion. First patient, 29-year-old pregnant female, initially suspected for metastatic
medullary thyroid cancer, was eventually diagnosed with mixed cellularity type of thyroid HL. Second patient, 22-
year-old woman with suspicion of advanced thyroid cancer, was in the end diagnosed with an extra-lymphatic
classical HL of the thyroid. In both cases, despite repeated fine-needle aspiration biopsy, cytological examination
gave inconclusive or misleading results. On histopathological examination, thyroid tumor cells were positive for
CD15 and CD30 antigen, which is typical for Reed-Sternberg cells. In the report authors also discuss difficulties in
management as well as potential importance of novel methods such as FISH, PCR and other molecular techniques
in diagnostics of thyroid lymphomas.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2896947559559648
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Hodgkin lymphomas (HL) is a biologically heteroge-
neous group of neoplasms. The incidence of HL in
European Union is estimated at about 2.2-2.7/100 000
cases per year, constituting 11.7% of all lymphomas diag-
nosed in 2006 [1]. The majority of cases is in low-stage
disease and presents the nodular sclerosis subtype.
An increase in incidence of extra-nodal lymphomas has
been observed over the past two decades [2]. Extra-nodal
origin is more common in NHL and may reach 33% [3].
On the other hand, HL mainly arises in lymph nodes of
the neck and mediastinum, while only approximately 5%
develop in extra-nodal sites, including tonsils, nasopha-
rynx, parotid glands, thyroid, parathyroid or nasal antrum,
with or without concomitant nodal involvement [4].* Correspondence: mruchala@ump.edu.pl
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distribution, and reproduction in any mediumThe head and neck is a third place of extra-nodal
localization of the lymphomas [5]. Lymphomas account
for less than 5% of malignant lesions diagnosed in the
thyroid identified in about two cases per million [6,7].
Vast majority of them are B-cell non-Hodgkin lymph-
omas (NHL), developing in the course of autoimmune
thyroiditis, while HL primarily localized in the thyroid, is
a very rare finding [8,9].
Extra-nodal lymphomas (ENL) represent different
pathologic, imaging, and clinical features as well as dis-
similar prognosis from nodal lymphomas, and should
therefore be distinguished [10]. Extra-nodal involvement
is much less common in HL compared with NHL. ENL
more often spreads by continuity from contiguous nodal
disease, while haematogenous spread is rare, occurring
in 5%-10% of patients [11].
Hodgkin lymphoma of the thyroid is uncommon and
accounts for 0.6-5% of all thyroid malignancies and 2-7%
of all ENL [12-15]. In vast majority primary thyroidMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Histopathological examination of the material
obtained during thyroidectomy - Hodgkin lymphoma - mixed
cellularity (MC) type in Patient 1 (H&E, magnification × 10).
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lymphomas derive from T-cell lymphocyte [12,16].
Factors leading to the development of thyroid lymph-
oma are not fully understood. Some authors attempt to
relate a significant prevalence of women with thyroid
HL to autoimmune thyroiditis [16]. It is considered, that
thyroid lymphoma develops from lymphocytic tissue
present in the gland only in case of autoimmune thyroid
disease, while normal thyroid gland is devoid of native
lymphoid tissue [17]. Hashimoto thyroiditis is detected
in 27% to 100% of thyroid lymphoma cases [18]. On the
other hand, less than 1% of patients suffering from
Hashimoto disease come down with lymphoma [19,20].
It is estimated, that a period of 20 to 30 years is needed
for lymphoma to develop in case of thyroiditis [17]. In the
largest study of patients with HL by Wang et al., 7 out of
21 subjects presented Hashimoto thyroiditis [8].
Among factors, which may play role in the development
of thyroid lymphoma, the prolonged antigen stimulation
as well as aberrant somatic hypermutation are mentioned
[21-24]. Ebstein-Barr virus (EBV) infection is also men-
tioned as etiological factor, since 20-100% of systemic HL
is thought to be associated with EBV infection; more likely
in mixed cell and lymphocyte depletion types of HL.
Moreover, HHV-6 can be detected in 48% of Reed-
Sternberg (R-S) cells of nodular sclerosis HL and is
considered as another factor potentially promoting de-
velopment of this type of HL [25].
It remains a matter of debate whether thyroid gland in
these cases is a primary site of HL origin or a secondary
organ involved in the disease [8]. Organ specific HL
without concomitant lymph nodes involvement is ex-
tremely rare [26]. In our paper we aim to focus on sub-
jects, in whom the diagnosis of HL was made in the
course of evaluation of a thyroid lesion and later on in-
volvement of other sites was detected.
Here we present two cases of Hodgkin lymphoma,
initially manifesting as thyroid lesions.
Case report
Patient 1
In April 2002, 29-year-old pregnant woman was referred
for ultrasound examination of the neck due to consider-
ably enlarged cervical lymph nodes detected on palpa-
tion. On sonography the packages of lymph nodes with
coinciding hypoechogenic ill-defined thyroid lesion were
demonstrated, what raised suspicion of advanced thyroid
cancer. Patient underwent fine-needle aspiration biopsy
(FNAB) of both thyroid lesion and lymph nodes. The re-
sult of cytological examination was consistent with sus-
picion of medullary thyroid cancer. At the time of
diagnosis, the patient was 29 weeks pregnant with her
first baby. Due to suspicion of metastatic medullary thy-
roid carcinoma, decision on surgical treatment wasmade, despite the patient was in the third trimester. The
total thyroidectomy with lymphadenectomy was per-
formed, with coordinated care of an anesthesiologist and
a gynecologist, constantly monitoring the welfare of both
mother and fetus. Perioperative period was uneventful.
Post-operative immunohistochemical and histopatho-
logical examinations revealed, that previously observed
immunostaining for calcitonin was falsely positive in
lacunar cells and lymphocytes. Thyroid tumor cells
expressed antigen CD15 and CD30, which is typical for
R-S cells, being a marker of HL. Thus, final diagnosis of
mixed cellularity (MC) type HL of the thyroid was
established (Figure 1). Only retrospective verification of
the specimen obtained during preoperative FNAB, re-
vealed the presence of R-S cell (Figure 2). Consulting
hematologist decided to postpone chemotherapy for the
time after delivery. In the 36th week of pregnancy, the
symptoms of preterm labor occurred and the patient de-
livered a healthy boy by caesarean section. Three weeks
later the patient was admitted to the department of
hematology, where thorough clinical evaluation, bone
marrow biopsy and imaging studies were performed to
establish the advancement of the disease. The patient
presented involvement of cervical and thoracic lymph
nodes, splenomegaly and clinical symptoms (fever >38°C
and sweating), hence IVB stage of HL according to Ann
Arbor classification was diagnosed. She received 8
courses of ABVD (Adriamycin, Bleomycin, Vinblastine,
Dacarbazine) chemotherapy and reached remission. Dur-
ing 10-year follow-up period, no relapse of lymphoma
was detected. Four years following the therapy, the pa-
tient got pregnant and gave birth to healthy female
twins. She is still followed up in an endocrine outpatient
clinic and her hormonal balance is maintained with
100 μg of L-thyroxin.
Figure 2 Retrospective verification of cytological specimen
obtained preoperatively during fine-needle aspiration biopsy
of the thyroid in the Patient 1. An arrow indicates Reed-Sternberg
cell, presence of which might provide preoperative diagnosis of
Hodgkin lymphoma (H&E, magnification × 400).
Figure 3 Histopathological examination of the material
obtained during thyroidectomy - Hodgkin lymphoma - nodular
sclerosis (NS) type in Patient 2 (H&E, magnification × 10).
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23-year-old woman came to a laryngologist with painless
bilateral enlargement of neck lymph nodes and hoarse-
ness. Despite prescribed antibiotic therapy, symptoms
persisted, thus ultrasound examination of the neck was
performed, which demonstrated thyroid lesion with con-
comitant involvement of lymph nodes. Subsequently the
patient was referred to the endocrinology outpatient
clinic with suspicion of advanced thyroid cancer in
September 2008. On thyroid ultrasound examination, a
large (32x30 mm), hypoechogenic lesion, localized at the
border between left thyroid lobe and isthmus, was visu-
alized. Unilaterally, package of enlarged, round and
hypoechogenic lymph nodes of size 20×12 mm was
found, suggesting metastatic lesions. The trachea was
displaced to the right side. On thyroid scintiscan, a large
cold nodule was found and its localization corresponded
to the lesion revealed during ultrasonography. The chest
X-ray disclosed the enlargement of the upper mediasti-
num (to 70 mm). There was no past history of thyroid
or hematologic disease. Her family history was non-
contributory. At the time of diagnosis the patient was
euthyroid and thyroid autoantibodies were negative.
Other laboratory tests revealed accelerated ESR and in-
creased concentration of white blood cells with deple-
tion of lymphocytes and eosinophils. Thyroid and lymph
nodes FNAB was performed three times. The cytological
examination of initial two specimens gave non-diagnostic
result due to too small amount of cells obtained in the
specimens. Eventually, the third biopsy allowed to detect
suspected cells of undetermined origin. The clinical pic-
ture, together with results of imaging studies and cyto-
logical examination, prompted us to refer the patient for
immediate total thyroidectomy with lymphadenecto-my. Immunohistochemical studies were performed and
showed the tumor cells expressing CD30+, CD15+, Ki67+.
Tumor cells were negative for D3-, CD20-, CKAE1/3,
EBV-LMP1. Thus a final diagnosis of extra-lymphatic clas-
sical HL (nodular sclerosis subtype) of the thyroid was
made (Figures 3 and 4).
The patient was subsequently referred to the depart-
ment of hematology. On the base of clinical picture, im-
aging examinations and bone marrow assessment, she
was classified for stage IIE of disease in Ann Arbor clas-
sification. The patient was subjected to combined che-
motherapy (12 cycles of ABVD) and radiotherapy,
starting from December 2008. The following imaging
studies, including chest X-ray and positron emission
tomography were performed to confirm remission status
and did not reveal any pathological changes. The pa-
tients observation period has now reached four years
and is uneventful. She continues to be followed-up in an
endocrinology outpatient clinic and remains both clini-
cally and biochemically euthyroid on substitutive 125 μg
dose of L-thyroxin.
Discussion
Neoplasms diagnosed in the thyroid gland are usually
primary thyroid cancers, while lymphomas account for
less than 5% of malignant lesions diagnosed in the thy-
roid. Vast majority of them are B-cell non-Hodgkin
lymphomas (NHL), developing in the course of auto-
immune thyroiditis, while Hodgkin lymphoma (HL), pri-
marily localized in the thyroid, is a very rare finding
[12-14]. However, in differential diagnosis also rarely oc-
curring tumours of this localization need to be involved
[27-31]. The thyroid gland constitutes an uncommon
site for metastatic changes from various primary sites.
Thyroid metastases are encountered in 2% to 24% of the
Figure 4 Reed-Sternberg cells positive for CD 30 in Patient 2
(H&E, magnification × 10).
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nosis of thyroid lesions should also comprise other un-
common primary thyroid tumors. Leiomyosarcomas of
the thyroid account for 6% of the all head and neck tu-
mors, with 18 cases described so far in the world litera-
ture [29]. Primary squamous cell carcinoma (SCC) of
the thyroid is also an extremely rare entity, observed in
less than 1% of all thyroid malignancies [30]. Vascular le-
sions include benign tumors such as hemangiomas and
malignant ones including angiosarcomas or undifferenti-
ated angiosarcomatoid carcinomas [31].
Our extensive literature search revealed thirty seven
cases of HL located in the thyroid gland reported to
date. In patients with thyroid HL women predominate
and constitute about 75-80% of reported patients [4,32],
while systemic HL has an equal male to female ratio. In
the paper describing the largest series of subjects with
thyroid HL by Wang et al., an average age of a patient
with HL of the thyroid gland was 42 (with range from
18 to 64) and was lower than for NHL (7th decade) [8].
About two thirds of patients suffering from thyroid HL
were younger than 45 years old [33]. It is consistent with
what we learned from our patients, who were diagnosed
even below the age of thirty.
As we mentioned above, autoimmune thyroiditis is
one of the factors linked with development of lymph-
omas. Our two patients with thyroid HL presented nei-
ther laboratory nor cytological features of thyroid
inflammation. Thyroid HL in over 80% of patients mani-
fests as a rapidly enlarging unilateral or bilateral neck
mass. Other clinical symptoms include: hoarseness
(35%), dyspnea (65%) and dysphagia (53%) [28]. HL of
the thyroid may present as diffuse involvement of the
gland or a focal lesion [29]. Both our patients presented
enlargement of neck lymph nodes and the second one
also has been complaining about hoarseness. Similarly toour patients, on physical examination in most cases thy-
roid tumor tends to be firm to hard upon palpation [30].
Vast majority of formerly reported patients with HL
presented concomitant neck lymph nodes involvement
at the time of diagnosis, but the presence of B-symptoms,
including inter alia fever and sweating occurring in one of
our patients, at the same time is relatively rare (33%) [16].
B-symptoms may develop in the course of lymphoma and
are usually associated with systemic involvement and con-
stitute a marker of negative prognosis. These include
temperature >38°C (>100.4°F) for three consecutive days,
weight loss exceeding 10% of body weight in 6 months
and drenching night sweats.
Patients with thyroid HL are mostly euthyroid or less
often hypothyroid (30-40%) at the time of diagnosis [34].
Both our patients presented normal thyroid function.
On scintiscan HL localized in the thyroid presents as a
cold nodule, while ultrasound examination reveals dif-
fused or focal thyroid enlargement, mimicking thyroid-
itis or primary thyroid lesion [8]. In case of the first
patient, scintiscan was contraindicated because of preg-
nancy. A large cold nodule was found on thyroid scinti-
scan of the second patient. The involved lymph nodes
are homogeneous, variable in size and might display ne-
crosis and calcifications [4]. On ultrasound examination,
enlarged lymph nodes were found in both described
cases. However, despite increased size and formation of
packages, no other suspected features of lymph nodes
were demonstrated.
The difficulty in diagnosis poses the fact, that if the
personal history is negative for hematologic diseases, the
thyroid lymphoma is rarely suspected. Diagnosis of
lymphoma should be considered when dealing with rap-
idly enlarging goitre. The FNAB constitutes the initial
examination used for evaluation of thyroid lesion. Its
role is limited but the procedure is necessary for both
immunocytochemical studies and flow cytometry. Pri-
mary thyroid HL should be suspected when the speci-
men consists of lymphocytes, but carcinoma cannot be
excluded. The reports on the efficacy of FNAB in diag-
nostics of thyroid lymphomas provide diverse results.
According to different studies, 50-80% of cases of thy-
roid lymphomas is revealed on the basis of FNAB results
[7,13,35-38]. However, Gupta et al. reported that in nine
out of ten cases, a diagnosis of NHL was made on the
base of FNAB [13]. Only in one case, in a patient pre-
senting diffuse swelling, cytology demonstrated a poly-
morphic infiltrate consistent with reactive hyperplasia
and the diagnosis of lymphoma was missed [13]. In the
study by Dedecjus et al., the proper diagnosis of thyroid
lymphoma was made in less than 50% of cases in US-
guided FNAB, while in other study by Seningen et al.,
the FNAB characterized with very high specificity and
positive predictive value at the level of 99.6% and 88.9%,
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diagnosis of large cell type lymphoma is simple on
FNAB due to build of large cells, lack of cellular cohe-
sion and lymphoglandular bodies in the background
[13]. On the contrary, diagnosis of MALT- lymphomas
basing on cytology is difficult due to heterogeneous ap-
pearance of the neoplastic infiltrate [40].
Differentiation of primary thyroid lymphoma from
thyroid cancer and Hashimoto thyroiditis may produce a
diagnostic dilemma. Low accuracy of FNAB comes out
of hypocellular samples, small population of R-S cells,
marked fibrosis and sclerosis, resemblance between the
R-S cells and inflammatory cells and, finally, very rare
incidence of thyroid HL [8]. Immunocytochemistry
should be used to confirm the suspicion of lymphoma
[41]. Small biopsy probes may lead to diagnosis of thy-
roiditis instead of lymphoma, due to presence of neutro-
phils, abscess or necrosis [42]. It remains a challenge to
differentiate between benign and malignant lymphoid in-
filtrate [19]. FNAB constitutes a helpful initial diagnostic
device to establish the preliminary diagnosis, however is
not sufficient for the final one, because the evaluation of
lymph node architecture is extremely important [43,44].
What is more, in HL the tumour cells represent the mi-
nority of the cellular population, where normal reactive
lymphocytes, eosinophils, and histiocytes predominate.
Hence, cytological specimen obtained during FNAB may
not contain the R-S cells, indispensable for adequate
diagnosis [44]. Lymphomas may differ from Hashimoto
thyroiditis with the abundance of lymphoid tissue and a
high proportion of intermediate centrocyte-like cells, es-
pecially in low-grade NHL. A sampling error and coex-
istence of Hashimoto thyroiditis and lymphoma might
cause false-negative results [40].
The diagnostic accuracy of FNAB of lymph node is
evaluated from 30 to 92%. The main limitations are fi-
brosis and abundant benign surroundings [42,45]. It is
reported in the literature that a single-tube flow cytome-
try can be used in screening of classic HL in tissue body
sections or FNAB specimens with 88% sensitivity and
even 100% specificity [42,46]. Other corroborative methods
include tissue biopsy and surgery.
Contemporary development in diagnostics allow to in-
crease the diagnostic accuracy of cytological examination
in lymphomas. Immunocytochemistry allows for confir-
mation of the lymphoid origin of the cells and their B or
T-lineage [13]. Flow cytometry is a well-adapted method
to establish the immunophenotype in FNAB specimens
[19,47]. In case of lymph nodes, flow cytometry characte-
rizes with high sensitivity and specify, ranging from 94 to
100% [47-50]. However, in flow cytometry-based diagnosis
of the thyroid gland lesions, elevated κ:λ ratios have been
observed in many case of thyroiditis, what can produce a
diagnostic dilemma [51].Ochs et. al stress that genetic testing, including poly-
merase chain reaction (PCR) and florescence in situ
hybridization (FISH) is feasible and useful tool in diag-
nosis of thyroid lymphomas [19]. Identification of ge-
netic abnormalities can be critical to the diagnosis of
lymphoma, especially this of unusual site of origin like
lymphomas of thyroid gland [19]. Endocrinologists fre-
quently have to make a decision solely on the basis of
FNAB hence the use of molecular testing in limited ma-
terial obtained during FNAB is very helpful to establish
diagnosis prior to invasive procedures [19]. PCR-based
methods constitute important diagnostic method in
cases when flow cytometry does not allow to reveal
clonality of the cells. Clonality testing can be applied for
indicating the relationship between sites in multifocal
disease [19]. R-S cells account for only 0.1-1% of the
cells in material obtained during FNAB [52]. Molecular
techniques targeting these cells provide some information
on cytogenetic aberrations in HL [52]. However, immuno-
globulin heavy chain genes should be interpreted with
attention due to frequency of monoclonal rearrange-
ment in thyroiditis [53].
Genomic gains in chromosom arm 2p, including REL
gene and gains in 9p are present in 30 to 50% of classic
HL [54-57]. Chromosomal breakpoints affecting im-
munoglobulin loci are recurrent in B-cell lymphomas,
but also classical HL. In about 17% of R-S cells, Martin-
Subero et al. observed breakpoints in IGH, IGL or IGK
locus [52,57].
Other molecular cytogenic technics useful in diagnostic
process of HL apart from FISH and PCR include compara-
tive genomic hybridization (CGH) from microdissected
R-S cells, fluorescence immunophenotyping and inter-
phase cytogenetics (FICTION) as a tool for the investi-
gation of neoplasms [52].
In case of our two patients FNAB failed to bring the
preoperative diagnosis of HL. Unfortunately, none of the
above described advanced techniques supporting cyto-
logical examination were at the moment of evaluation of
the described patients a part of routine diagnosis at our
department. In Patient 1, non-specific staining for calci-
tonin resulted in misdiagnosing medullary thyroid can-
cer, and only during the retrospective re-evaluation of
the cytological material obtained during FNAB, R-S cell
was identified. Incidence of calcitonin-containing cells in
thyroid lymphoma and in Hashimoto thyroiditis was
already described by Baschieri et al. [58]. C cell hyperpla-
sia is present frequently in lymphomas and shows positiv-
ity for calcitonin. Hyperplastic C cells are not observed in
Hashimoto thyroiditis. Hence, an increase in the C cell
number might be a marker of thyroid lymphoma [58].
In Patient 2, the repeated FNAB did not allow to obtain
the number of cells high enough to establish diagnosis.
Hence, without clinician’s suggestion and experience of
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gland is limited.
Final pathological diagnosis should be made from surgi-
cal specimen or excisional lymph node biopsy and should
be based on WHO classification [25,59]. One of the basis
of histopathological diagnosis of HL is the identification of
the presence of R-S cells. These are large mutated cells,
derived from B lymphocytes, presenting with an am-
phophylic cytoplasm and multiple or a bilobed nucleus,
eosinophilic inclusion-mimicking nucleoli, devoid of typ-
ical B-cell markers such as CD20 and CD79a. Their char-
acteristic immunophenotype is of crucial importance in
diagnosis of HL. A CD 30 antigen is typical for R-S cells,
while CD 15, an antigen normally expressed in monocytes
and granulocytes, but not in lymphocytes, is present at
R-S cells in 75-85%, independent of the type of HL [60,61].
Classical HL, which constitutes about 95% of all HL
cases, can be divided into nodular sclerosis, mixed cellu-
larity, lymphocyte-rich and lymphocyte depleted sub-
types [25]. Staging is estimated according to the Ann
Arbor system and it determines prognosis and validity of
radiotherapy [59]. Most patients present stage I or II of
the disease and the nodular sclerosis subtype [8]. There
were only two cases of mixed cellular subtype of HL
involving the thyroid reported so far in the literature
and to our knowledge, one of our patients would be a
third case [8,62].
The literature search reveals that surgical removal of
the thyroid affected with HL does not influence the
prognosis [22,44]. HL responds quickly to chemotherapy
and radiotherapy, while surgical risk is considered un-
necessary [22,32]. However, excision of the lesion can be
of importance in cases with acute airway obstruction
[34]. Preoperative diagnosis is not always established,
hence, due to similar clinical picture of hypoechogenic
lesion of the thyroid, presenting as cold nodule in the
scintiscan, the patient is referred for thyroid surgery with
suspicion of primary thyroid cancer, as it was in case of
both our patients. The nodal involvement additionally
suggests metastatic disease. Hence, if the presurgical
diagnosis of HL is reached, the operation is not re-
commended. However, in both our cases, cytological
examinations was not conclusive, hence surgery and
histopathological examination was the only way to deter-
mine the diagnosis.
With appropriate therapy, primary thyroid HL is asso-
ciated with favourable prognosis. Nowadays, chemo-
therapy (ABVD) and 30 Gy radiotherapy is the
treatment of choice in primary thyroid lymphoma
[25,63]. The final outcome depends on the histological
type and stage of the disease at presentation. The sur-
vival is significantly greater for HL than for NHL [16]. It
was determined, that both high value of ESR (over
50 mm/h without systemic symptoms) and extra-nodalinvolvement independently constitute important pre-
treatment prognostic factors in subjects with HL [2,64].
One of our patients presented markers of unfavourable
prognosis such as ESR 71 mm/h and both had extra-
nodal localization of the lymphoma. However, at the mo-
ment of publication, both patients were in remission for
ten and four years, respectively.
Conclusions
To conclude, despite its rarity, Hodgkin lymphoma ought
to be considered in differential diagnosis of thyroid lesions.
An appropriate preoperative diagnosis prevents from un-
necessary total thyroidectomy. Hodgkin lymphoma that
initially presents as a thyroid mass, treated with combined
modality therapy has favourable outcome.
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